Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
272
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Correlation Study on HLA-DR and CD117 (c-Kit) Expressions: Its Prognosis and Treatment Response in Acute Myeloid Leukemia Patients

Yomna M El-Meligui1 Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, EgyptORCID Iconhttps://orcid.org/0000-0001-6848-5743
ORCID Icon,
Heba E Abd Elrhman2 Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt
,
Ahmad Salahuddin3 Biochemistry Department, Faculty of Pharmacy, Damanhour University, Damanhour, EgyptORCID Iconhttps://orcid.org/0000-0002-7382-4284
ORCID Icon,
Manal Ali Hamouda4 Clinical Pharmacy Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt
&
Amira B Kassem5 Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Damanhour University, Damanhour, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4195-6036
ORCID Icon
Pages 381-393 | Published online: 30 Mar 2021

References

  • Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(1):89–99. doi:10.1002/ajh.22246
  • Elshoura OA, Elkholy RA, Selim AE, et al. Prognostic significance of tetraspanin (CD81) expression in patients with acute myeloid leukemia. Egypt J Haematol. 2018;43(4):151.
  • Boyer T, Guihard S, Roumier C, et al. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget. 2016;7(38):62377. doi:10.18632/oncotarget.11481
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
  • Sharawat SK, Gupta R, Raina V, et al. Increased coexpression of c‐KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia. Cytometry Part B Clin Cytometry. 2013;84(6):390–397.
  • Tarlock K, Eidenschink Brodersen L, Alonzo TA, et al., CD117 expression is associated with cytogenetic and molecular profiles and outcome in pediatric acute myeloid leukemia. Washington, DC: American Society of Hematology; 2019.
  • Seliger B, Kloor M, Ferrone SJO. HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance. Oncoimmunology. 2017;6(2):e1171447.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
  • Yalniz F, Abou Dalle I, Kantarjian H, et al. Prognostic significance of baseline FLT3‐ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019;94(9):984–991. doi:10.1002/ajh.25553
  • Gupta M, Mahapatra M, Saxena R. Cytogenetics’ impact on the prognosis of acute myeloid leukemia. J Lab Physicians. 2019;11(2):133. doi:10.4103/JLP.JLP_164_18
  • Abdel Hamid TM, El GammalMM, Eibead GT, et al. Clinical Impact of SNP of P53 Genes Pathway on the Adult AML Patients. Hematology. 2015;20(6):328–335.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649. doi:10.1200/JCO.2003.04.036
  • Ge F, Li B, Gao X, et al. Immuno-phenotypes and prognosis of acute leukemia in elderly patients. Int J Clin Exp Med. 2014;7(10):3714.
  • Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475–486. doi:10.1200/JCO.2010.30.2554
  • Rastogi P, Sachdeva MU. Flow cytometric minimal residual disease analysis in acute leukemia: current status. Indian J Hematol Blood Transfusion. 2020;1–13.
  • Peker D. Navigating through mutations in acute myeloid leukemia. what do we know and what do we do with It? Erciyes Med J. 2018;40(4):183–187. doi:10.5152/etd.2018.18136
  • Heo S-K, Noh EK, Kim JY, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep. 2017;7(1):1–12.
  • Mendoza AS, Qing X, Dungo M, et al. HLA-DR antigen-positive acute promyelocytic leukemia. Exp Mol Pathol. 2016;101(2):197–200.
  • Mosleh M, Mehrpouri M, Ghaffari S, et al. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLA-DR negative Non-APL leukemia. Scandinavian J Clin Lab Invest. 2020;80(2):87–92. doi:10.1080/00365513.2019.1700427
  • Abdul Hamid G, Akrabi M. Aberrant Antigen Expression in Patients with Acute Leukemia. EC Clinical and Medical Case Reports. 2019;2:53–56.
  • Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 2003;17(4):707–715. doi:10.1038/sj.leu.2402865
  • Xiao S, Zhu HJBR. Correlation study on CD7, CD34, CD56 and HLA-DR expressions and its prognosis among patients with acute myeloid leukemia. Biomedical Research. 2017;28(15). doi:10.1111/ina.12430
  • Mori H, Sakai H, Sanada M, et al. Clinical analysis of HLA-DR-negative non-M3 AML. Jpn J Clin Hematol. 2007;48(7):547–553.
  • Krishnan S, Li H, Mourad YR, et al.. Elderly AML patients treated with intensive chemotherapy-developing a prognostic scoring system. a study on 381 patients from British Columbia. American Society of Hematology; 2011.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.